Skin Cancer

Expert faculty review and share their insights and perspectives on key findings in skin cancers presented at the 2022 ASCO Annual Meeting.

Share

Program Content

Activities

  • ASCO 2022: Key Skin Cancer Studies
    Key Studies in Skin Cancer: Independent Conference Coverage of the 2022 ASCO Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 29, 2022

    Expires: August 28, 2023

Activities

NeoTrio
NeoTrio: Neoadjuvant Pembrolizumab Alone, Combined With, or in Sequence With Dabrafenib and Trametinib in Resectable BRAFV600-Mutant Stage III Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

RELATIVITY-047: Subgroup Analysis
RELATIVITY-047: OS and ORR by Key Subgroups in Patients With Advanced Melanoma Receiving First-line Relatlimab + Nivolumab vs Nivolumab Alone
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

KEYNOTE-716 Update
KEYNOTE-716: Update of the Phase III Trial of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

SWOG 1512
SWOG 1512: Phase II Study of Neoadjuvant Pembrolizumab in Patients With Resectable Desmoplastic Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

Tebentafusp + Anti–PD-L1: Cutaneous Melanoma
Tebentafusp ± Durvalumab and/or Tremelimumab in Metastatic Cutaneous Melanoma: Updated OS Analysis From IMCgp100-201 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

CAM/APA/TMZ in Acral Melanoma
First-line Camrelizumab, Apatinib, and Temozolomide in Advanced Acral Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

PRADO
PRADO: Phase II Trial of Response-Directed Surgery and Adjuvant Therapy Following Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

TRICOTEL
TRICOTEL: Phase II Study of Atezolizumab, Cobimetinib, and Vemurafenib in BRAFV600-Mutated Melanoma With CNS Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

CheckMate 067: 7.5-Yr Update
CheckMate 067: Long-term Survival and HRQoL With First-line Nivolumab ± Ipilimumab in Advanced Melanoma at 7.5-Yr Follow-up
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

AMBER Parts 1C and 1E
AMBER Parts 1C and 1E: Phase I Trial of Cobolimab, an Anti–TIM-3 mAb, Plus Dostarlimab in Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2022

Expires: June 19, 2023

Faculty

cover img faculity

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

cover img faculity

Hussein Tawbi, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.